ETHRIS

Germany
Planegg, Bavaria, Germany, 82152

Company profile

ETHRIS company profile

ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent.

Business identity

Contact email
[email protected]
Phone number
+4908989557880
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$0+
Founded
2009-01-01, Year

Headquarters

Postal code
82152
Country code
DE
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
9
Total equity funding
$76.8M
Last funding
Grant / $11.3M / 2025-05-06
Last equity funding
Series Unknown / $5M
Investors
8
Lead investors
4
Founders
2
Articles
42

Founders and investors

Founders

PD Dr. Carsten RudolphProf. Dr. Christian Plank

Lead investors

Bill & Melinda Gates FoundationCiplaEuropean CommissionLaureus Capital

Investors

AstraZenecaBill & Melinda Gates FoundationCiplaEuropean CommissionOrbiMed